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Abstract
To date, no plaque-derived blood biomarker is available to allow diagnosis, prognosis or monitoring of atherosclerotic
vascular diseases. In this study, specimens of thrombendarterectomy material from carotid and iliac arteries were incubated
in protein-free medium to obtain plaque and control secretomes for subsequent subtractive phage display. The selection of
nine plaque secretome-specific antibodies and the analysis of their immunopurified antigens by mass spectrometry led to
the identification of 22 proteins. One of them, junction plakoglobin (JUP-81) and its smaller isoforms (referred to as JUP-63,
JUP-55 and JUP-30 by molecular weight) were confirmed by immunohistochemistry and immunoblotting with independent
antibodies to be present in atherosclerotic plaques and their secretomes, coronary thrombi of patients with acute coronary
syndrome (ACS) and macrophages differentiated from peripheral blood monocytes as well as macrophage-like cells
differentiated from THP1 cells. Plasma of patients with stable coronary artery disease (CAD) (n = 15) and ACS (n = 11)
contained JUP-81 at more than 2- and 14-fold higher median concentrations, respectively, than plasma of CAD-free
individuals (n = 13). In conclusion, this proof of principle study identified and verified JUP isoforms as potential plasma
biomarkers for atherosclerosis. Clinical validation studies are needed to determine its diagnostic efficacy and clinical utility
as a biomarker for diagnosis, prognosis or monitoring of atherosclerotic vascular diseases.
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Introduction
Atherosclerosis with its complications such as acute coronary
syndrome (ACS), sudden cardiac death and stroke, is the leading
cause of death world-wide. While fatty streaks develop into
atheroma and then into complicated atherosclerotic plaques
without significant lumen obstruction [1], the patient does not
display any symptoms and therefore is often unaware of the risk. In
about half of patients, the first manifestation of coronary
atherosclerosis is sudden cardiac death or myocardial infarction
unheralded by any symptoms [2]. To date, clinical laboratory
diagnostics provides important information for cardiovascular risk
assessment (notably total-, HDL- and LDL-cholesterol and
triglycerides, as well as C-reactive protein (CRP)), acute diagnosis
(troponins I or T) and prognosis (e.g. troponins or B-type
natriuretic peptides) of coronary artery events [3,4,5]. However,
the diagnostic and prognostic value of these biomarkers is
hampered by their limited sensitivity and/or specificity [6,7].
Moreover, progression and regression of atherosclerotic vascular
diseases can currently be assessed only by expensive imaging
techniques [8,9], which sometimes are even invasive, but not by
measuring any reasonably priced disease marker in blood. Hence,
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there is still a high medical need for novel biomarkers that identify
asymptomatic patients at high risk for coronary events, to improve
the diagnostics of acute arterial disease events and to monitor the
progression of atherosclerosis under treatment.
Atherosclerosis is a systemic and frequently pan-arterial disease.
Histopathological studies [10,11] have unravelled strong correla-
tions between morphological and inflammatory indices as well as
lipid content between different arteries within an individual
person. Moreover, prospective studies demonstrated that the
plaque load or a previous vascular event in one vascular bed, for
example in the carotid artery, indicates a strongly increased risk
for the incidence of clinical events in another vascular bed, for
example the coronary arteries [11]. In this study therefore, we, like
others [10,12,13,14], used relatively easily accessible atheroscle-
rotic plaques for the proteomic search of biomarkers that are
intended to be used for risk prediction, diagnostics and monitoring
of atherosclerotic vascular diseases in other arteries or even in
general. Specifically, we combined subtractive antibody phage
display [15,16] with mass spectrometry (MS) to identify proteins
released from cultured atherosclerotic lesions into so-called
secretomes [17]. In initial verification studies, several isoforms of
one identified protein, namely junction plakoglobin (JUP), were
found to be expressed and released by endarterectomized plaques
and macrophages, and to be enriched in coronary thrombi as well
as in plasma samples of ACS and CAD patients.
Materials and Methods
Detailed methodological information is given in the on-line
supplementary information.
Ethics Statement
The use of the tissue material and plasma samples investigated
in this study was approved by the Cantonal Ethical Committees in
Basel and Zurich, respectively. All studies on human materials
were performed in accordance with the 1964 declaration of
Helsinki. Informed and written consent was obtained from the
donating patients.
Preparation of Secretome
Secretomes were prepared from thrombendarterectomy speci-
mens of carotid or iliac arteries [14] (Figure 1). In short, plaque
and control tissues were incubated separately in protein-free
medium for 24 hours. Subsequently, the media containing the
secreted proteins, the so-called secretomes, were collected and
used as antigens in subtractive antibody phage display.
Selection of Antibodies
Secretomes were biotinylated with EZ-Link Sulfo-NHS-LC-
Biotin. A large synthetic human phage-displayed single chain
variable fragment (scFv) library, ETH-2-Gold [2], containing 3
billion individual antibody clones, was amplified as described [18].
Prior to the selections, the library was depleted of clones binding to
some of the most common plasma proteins, including apo-
transferrin, holo-transferrin, immunoglobulin G, fibrinogen and
complement component 3.
Six selections (Figure 2) were done with two subtractive selection
rounds each. Each selection was performed with an atherosclerotic
and control secretome from a different patient. Subtraction was
achieved by first removing phages binding to control secretome
(i.e. secretome produced with the best preserved part of the tissue).
The remaining, unbound phages were subsequently panned
against the biotinylated plaque secretome from the same patient.
Bound phages were captured using magnetic streptavidin-coated
beads and eluted. E.coli TG1 was infected with the eluted phages
and the bacteria were plated on large 26TY agar plates
containing ampicillin and 2% glucose. Phages were amplified
from E.coli TG1 to be used in a second round. Two subtractive
panning rounds were performed per selection. Polyclonal phage
pools of each round were screened in an enzyme-linked
immunosorbent assay (ELISA) for reactivity with control and
plaque secretome.
Screening of Single Clones
More than 500 single colonies were picked to produce
monoclonal phages and the selected phages were tested for their
ability to differentiate between plaque and control secretomes in
ELISA. In addition, expression levels of soluble scFv were analysed
by dot blotting and the cDNA encoding the scFvs of interest were
sequenced.
Production of Soluble scFv
The 34 clones showing the strongest difference in reactivity
were cloned into a new vector and expressed as single chain
variable fragment (scFv) with a 66-His-tag and a VSV-G-tag,
which replaced the original myc-tag. Soluble scFvs were induced
with IPTG and isolated from the E.coli periplasm by sucrose
extraction [19].
ELISA
Reactivity of polyclonal phages, monoclonal phages and scFvs
were analysed by ELISA. Antigens were coated on 96-well
Maxisorb microtiter plates (Nunc) at a concentration of 0.1 mg/
well in 100 ml of 50 mM carbonate buffer pH 9.6, overnight at
4uC. Plates were blocked with 400 ml MPBS containing 0.05%
Tween 20 (MPBST) per well at RT for 2 hours. Phages and scFvs
were diluted in MPBST and 100 ml were added to the plate and
incubated at RT for 1 hour. The plates were washed eight times
with PBST. To detect bound phages, HRP-conjugated anti-M13
monoclonal antibodies (mAB) (Amersham Biosciences) were added
at a 59000-fold dilution in MPBST and incubated at RT for one
hour. To detect bound scFvs, anti-VSV-G or anti-myc antibodies
were added (29000-fold dilution), followed by incubation with
HRP-labelled rabbit anti-mouse antibodies, 29000-fold diluted.
Bound HRP-conjugated antibodies were detected by 3,39,5,59-
tetramethylbenzidine (TMB) conversion (Rockland Inc.). Reac-
tions were stopped with 1 M H2SO4, and the absorbance at
450 nm was measured.
Immunoprecipitation
Nine scFv antibodies with the strongest specificity for proteins in
the plaque secretomes were used as baits for immunoprecipitation
of their antigens in plaque and control secretomes. Proteins were
precipitated from mixtures of two plaque and control secretomes,
using magnetic Dynabeads for His-tagged proteins (Invitrogen)
that captured the His-tagged scFvs. For information on unspeci-
fically bound proteins, two control experiments were done. The
precipitation was once done with magnetic Dynabeads without
any antibody and once using unspecific scFv antibodies against
TWIST1. TWIST1 acts as a transcriptional regulator and inhibits
myogenesis [20] and has no known relationship with atheroscle-
rosis or heart disease. Immunoprecipitated proteins were subse-
quently analysed by mass spectrometry.
Protein Identification by Mass Spectrometry
All MS experiments were done at the Functional Genomics
Center Zurich (FGCZ), a service centre of the University of
Junction Plakoglobin, Biomarker of Atherosclerosis
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Figure 1. Thrombendarterectomy tissue for secretome production and immunohistochemistry. a) Tissue sample as it was received from
the surgical department. b) The tissue was separated into the plaque part (I) for production of the plaque secretome, and the best preserved part (II)
for production of the control secretome.
doi:10.1371/journal.pone.0047985.g001
Figure 2. Schematic presentation of the selection strategy. a) The phage library, containing billions of different phages, was amplified from the
bacterial stock. ScFvare fused tominorcoatprotein III andas suchdisplayedon thephagesurface.b) Ina subtraction step, thephage librarywas incubated
withsecretomefromthehealthycontrol tissue.Binders tocommonproteinswere removedinthisway.c)Phagesthatdidnotbindtothecontrol secretome
wereincubatedwiththeatheroscleroticsecretomeinthispanningstep.d)Unboundphageswerewashedoff,ande)boundphageswereelutedandusedto
infect a suitable E.coli strain (E.coli TG1). f) Bacteria infectedwith the selected and eluted phages were plated on large agar plates. g) To further enrich for
phages that specifically bind to the atherosclerotic secretome, the selection roundwas repeated. h) Single colonieswere induced toproducemonoclonal
phages. i)Monoclonalphageswereanalysedfortheir reactivitywithatheroscleroticversuscontrolsecretomesinELISA. In total, sixdifferentselectionswere
performed. For each separate selection the control and atherosclerotic secretomes fromone individual patient were used. In order not to loose diversity,
only twosubtractivepanningroundswereperformedforeachselection.Toanalysewhetherenrichmentofatherosclerotic secretome-specificbindershad
takenplace,polyclonalphagepools (asobtained instepa)aftereachsubtractivepanninground(andof theunselected libraryasacontrol)wereanalysed in
ELISA for reactivity with atherosclerotic and control secretomes.
doi:10.1371/journal.pone.0047985.g002
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Zurich. Immunoprecipitated proteins were concentrated using a
speedvac system and dissolved in Laemmli buffer. Subsequently,
proteins were separated by SDS-PAGE on Novex 12% Tris-
Glycine 1 mm gels (Invitrogen) and stained with RotiBlue (Roth).
Each lane was cut into 12 segments and put into individual wells of
96-well plates. All further sample work-up was executed on a
liquid handling robot (TECAN). All gel pieces were subjected to
reduction of disulfide bridges with DTT, alkylation of cysteines
using iodoacetamide and in-gel trypsin digestion. The samples
were then concentrated in a speedvac system and purified using
ZipTip-mC18 (Milipore). Afterwards, the samples were pooled,
concentrated and stored dry at 220uC until MS analysis. Samples
were analyzed on an LTQ-Orbitrap XL mass spectrometer
(Thermo Fischer Scientific, Bremen, Germany) coupled to an
Eksigent-Nano-HPLC system (Eksigent Technologies, Dublin
(CA), USA). The obtained data were searched against a human-
contaminant database (human database including usual protein
contaminants) using Mascot Server 2.2.
Plasma Samples and Thrombi
Male subjects aged 54 to 65 admitted to the cardiac
catheterisation laboratory at the University Hospital Zurich
between December 2009 and October 2010 for coronary
angiography either for suspected coronary artery disease, ACS,
follow-up, or preoperatively before valve replacement or bypass
surgery, were included in the study [21]. Patient characteristics are
presented in Table 1. Four patients with peripheral artery
occlusion disease (PAOD) were seen at the Department of
Angiology at the University Hospital Zurich to undergo angiog-
raphy. All four patients had undetectable plasma concentrations of
(high-sensitive) cardiac troponin T. Thrombi were aspirated from
coronary arteries of three ACS patients during angiography.
Detection and Quantification of JUP and Other Candidate
Proteins by Immunoblotting
Albumin and immunoglobulins were removed from human
plasma samples with depletion columns (Qproteome columns,
Invitrogen). Thrombi were fragmented and directly dissolved in
SDS-PAGE loading buffer. After SDS-PAGE and Western
blotting, JUP was detected with scFv antibodies 25G5 via its
VSV-G-tag, or with anti-JUP monoclonal antibodies (mAb) 2C9,
which was later replaced by mAb 2G9, from Lifespan Biosciences
(Seattle, USA). As a positive control, GST-tagged recombinant
JUP from Abnova (Taipei City, Taiwan) was used. Intensities of
anti-JUP-immunoreactive bands were semi-quantitatively mea-
sured with ImageJ (National Institutes of Health [22]). To
compare signals of different Western blots, one reference plasma
sample was run on each gel for standardization. The intensities of
all JUP bands were correlated to the intensity of the anti-JUP-
immunoreactive band of this sample.
For rough JUP isoforms mapping the following antibodies were
used: polyclonal ab134558 from Abcam (Cambridge, England),
monoclonal LS-C21269, polyclonal LS-C118399, polyclonal LS-
C77817, polyclonal LS-B1216 and monoclonal LS-B4364 (2G9)
from Lifespan Biosciences (Seattle, USA), polyclonal CP2971 and
monoclonal CM1111 from ECM Biosciences (Versailles, USA),
monoclonal 610253 from BD Biosciences (Franklin Lakes, USA),
and monoclonal P8087 from Sigma Aldrich (Saint Louis, USA).
Serpin B3 and plexin domain-containing protein 2 (Plxdc2)
were detected by using commercial mAbs ab55733 from Abcam
(Cambridge, England) and 4G10 from Abnova (Taipei City,
Taiwan), respectively. Serpin B3 was also detected using the newly
generated VSV-G-tagged scFv antibodies 36A8. As positive
controls, GST-tagged recombinant serpin B3 and Plxdc2 from
Abnova (Taipei City, Taiwan) were used.
Immunohistochemistry
Tissue sections of coronary thrombi aspired from culprit
coronary arteries of two ACS patients as well as endarterecto-
mized atherosclerotic plaques were analyzed with the anti-JUP
mAb 2C9, anti-serpin B3 mAb ab55733, anti-Plxdc2 mAb 4G10
and anti-CD68 antibodies (Clone PG-M1).
Monocyte to Macrophage Differentiation
Peripheral blood monocytes were isolated from buffy coats
(Blutspendedienst Zurich, Switzerland) by separation over Histo-
paque and subsequent isolation with magnetic CD14 beads [23].
Isolated cells were resuspended in RPMI-1640 medium with 5%
fetal calf serum and 5% human serum (approximately 106 cells/
ml) and incubated in cell culture dishes. Cells were harvested at
days 2, 5, 7 and 9 and lysed in lysis buffer (50 mM HEPES
pH 8.0, 1 mM EDTA and 0.2% Triton X-100). GAPDH was
detected with a mAb from Abnova.
Human acute monocytic leukemia cells (THP1, DSMZ,
Germany) were plated in RPMI 1640 medium (Sigma) supple-
mented with 2 mM L-glutamine, 10% fetal bovine serum,
6.8 mM glucose, 1 mM sodium pyruvate and penicillin (100 U/
mL)/streptomycin (100 ug/mL) in petri dishes. Next, cells were
incubated with 200 nM phorbol-12-myristate-13-acetate (PMA) at
37uC and 5% CO2 for 1, 2, 3 and 4 days [23]. After the
differentiation period, non-adherent cells were removed and
remaining cells were harvested and lysed in ice-cold buffer
containing 50 mM TRIS (pH 7.4), 150 mM NaCl,
1 mM EDTA, 1% NP-40, 7.5% glycerol and complete protease
inhibitor cocktail (Roche) for 30 minutes. Finally, protein
concentrations in cell lysates were determined by Bradford protein
assay. b-Actin was detected with a mAb purchased from Sigma-
Aldrich (Saint Louis, USA).
Table 1. Patient characteristics.
Group
Control
(n= 13) CAD (n=15) ACS (n =11)
Age (y) 59.1+/24.3 59.9+/23.9 59.2+/24.9
BMI (kg/m2) 27.1+/29.4 28.2+/214 25.3+/224
Blood pressure systolic (mmHg)132+/210.2 133+/27.8 134+/217
Blood pressure diastolic
(mmHg)
80+/24.2 79+/24.3 84+/29.7
Total cholesterol (mmol/l) 4.33+/21.2 4.32+/20.85 5.02+/21.1
LDL cholesterol (mmol/l) 2.55+/21.10 2.54+/20.79 3.21+/20.85
HDL cholesterol (mmol/l) 1.30+/20.40 1.16+/20.23 1.14+/20.25
Triglycerides (mmol/l) 1.07+/20.60 1.36+/20.65 1.47+/21.10
C-reactive protein (mg/ml) 1.33+/21.03# 2.45+/23.6# 9.45+/210.3{{
Creatinine (mmol/l) 85+/29.8 93+/213.5 96+/232
#p,0.05 compared to ACS group.
{p,0.05 compared to control group.
{p,0.05 compared to CAD group.
BMI = body mass index, LDL = low density lipoprotein, HDL = high density
lipoprotein.
doi:10.1371/journal.pone.0047985.t001
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Artificial Myocardial Infarction by Ligation in Swine
In two swine that did not have any atherosclerosis, myocardial
infarction was artificially introduced by ligation (i.e. myocardial
infarction without the occurrence of plaque rupture). Plasma
samples were taken before (t = 0), three hours (t = 3 h) and three
days (t = 3 d) after ligation. Cardiac troponin T (TnT) increased
after ligation (data not shown).
Measurement of Other Blood Parameters
Plasma levels of high sensitive troponin T, NT-proBNP (Roche
E170), and CRP were measured by using the COBAS8000
autoanalyser and immunoassays from Roche diagnostics (Rotk-
reuz, Switzerland). Plasma concentrations of the endothelial
markers sVCAM-1 and soluble E-selectin were measured by
ELISAs from R&D Biosystems (Minneapolis, USA) following the
instructions of the manufacturer. Plasma concentrations of
squamous cells carcinoma antigen (SCC) were measured by using
an immunoassay on the Kryptor immunoassay analyser from
BRAHMS (Berlin, Germany).
Data Analysis and Statistics
Genevestigator TM [24] was used to explore known mRNA
expression of identified proteins in human tissues and cells. Patient
characteristics are given as mean and standard deviation. Non-
parametric statistical tests were used for testing of equality of the
biomarkers in the three patient groups (Mann-Whitney and
Kruskal-Wallis) and to calculate correlations between the bio-
markers (Spearman-Rho test).
Results
Phage Display-assisted Identification of 22 Proteins in
Plaque Secretromes
Secretomes were prepared by incubating atherosclerotic and
control tissues in protein-free medium for 24 hours (Figure 1). Six
separate selections were performed using six different pairs of
plaque and control secretomes, obtained from six different
patients, with two subtractive panning rounds in each selection
(Figure 2). Subsequently, more than 500 single clones of antibodies
expressing phages were analysed by ELISA. The genes of 40 scFvs,
which showed the strongest immunoreactivity with independent
sets of secretomes, were sequenced. Because of strong sequence
similarities or absent scFvs gene expression, six clones were
discarded. To allow immunodetection in plasma without interfer-
ence by endogenous myc, cDNAs of the 34 remaining scFvs were
re-cloned into vector pUC119 to replace myc-tags with VSV-G-
and 66-His-tags. After verification of the successful insertion scFvs
were produced in E.coli TG1 production strain and isolated from
Table 2. Overview of the 22 proteins identified by subtractive phage display combined with mass spectrometry.
Protein Function
Accession
number
Nr of
unique
peptides
Protein
coverage (%)
26S proteasome non-ATPase regulatory subunit 9 Chaperone during 26S proteasome assembly O00233 2 8.5
Alpha-2-macroglobulin Protease inhibitor P01023 3 2.2
Annexin A5 Coagulation inhibitor P08758 2 5.3
Caspase-14 Non-apoptotic caspase involved in epidermal
differentiation
P31944 2 8.7
cDNA FLJ60424, highly similar to junction plakoglobin Unknown B4DE59 4 * 13
cDNA FLJ78440, highly similar to human lactoferrin Unknown A8K494 13 12
Collagen alpha-1(I) chain Structural protein; member of group I collagens P02452 17 12
Collagen alpha-1(III) chain Structural protein; member of group III collagens P02461 2 1.6
Desmocollin-1 Structural component of intercellular desmosome
junctions
Q08554 4 4.9
Extracellular glycoprotein lacritin Modulates secretion by lacrimal acinar cells Q9GZZ8 2 17
Filaggrin-2 Regulation of epithelial homeostasis Q5D862 2 1.0
Glyceraldehyde-3-phosphate dehydrogenase Glycolysis; Trigger of apoptosis P04406 3 9.0
Junction plakoglobin Structural protein of desmosomes and intermediate
junctions
P14923 4 8.1
Keratin type I, cytoskeletal 17 Belongs to the intermediate filament family Q04695 7 26
Keratin type I, cytoskeletal 19 Belongs to the intermediate filament family; involved in
organization of myofibers
P08727 6 32
Keratin type I, cytoskeletal 78 Belongs to the intermediate filament family Q8N1N4 4 9.6
Keratin type I, cytoskeletal 80 Belongs to the intermediate filament family Q6KB66 3 8.2
Lipocalin-1 Belongs to lipocalin family (lipophile binders) P31025 4 21
Mucin-5AC Gel-forming glycoprotein of gastric and respiratory tract
epithelia
P98088 2 0.6
Nuclear receptor coactivator 1 Coactivator of different nuclear receptors Q15788 3 1.7
Plexin domain-containing protein 2 May play of role in tumor angiogenesis Q6UX71 4 6.6
Serpin B3 Protease inhibitor P29508 2 4.9
*2 peptides are shared with junction plakoglobin and 2 peptides are shared with keratin type I, cytoskeletal 19.
doi:10.1371/journal.pone.0047985.t002
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the periplasmic fractions. In subsequent ELISAs, nine of the 34
scFvs were found to react stronger with the plaque secretomes
than with the respective control secretomes from at least three of
four patients. They were, therefore, chosen for immunoprecipita-
tion of their antigens both in pooled control and in pooled plaque
secretomes. Two control experiments were performed by using
beads with either no or inert antibodies directed against TWIST1.
MS analysis identified 105 proteins that were specifically
immunoprecipitated by one of the scFvs in either the plaque or
the control secretome or both, but not by the inert anti-TWIST1-
antibodies or the antibody-free beads. 22 proteins (Table 2) were
identified in this affinity-enrichment approach, but not with direct
MS analysis of the secretomes. Genevestigator, a database
containing mRNA expression data, was used to explore the
expression of these 22 proteins in human cells and tissues. In this
way, some proteins could be excluded from further investigation,
as e.g. alpha-2-macroglobulin due to its high expression in liver.
Primary investigations, also because of the availability of
commercial antibodies, were focused on three out of the 22
proteins, namely junction plakoglobin (JUP), serpin B3, and plexin
domain-containing protein 2 (Plxdc2).
Serpin B3 and Plxdc2
Immunohistochemistry clearly demonstrated the presence of
serpin B3 in endarterectomised plaques (Figure S1a). A protein
band of 42 kD, corresponding to the molecular weight of serpin
B3, could be detected in plaque secretome, but not control
secretome, with a commercial mAb against serpin B3, although
also other protein bands were detected (Figures S1b and S1c).
Plasma analysis of serpin B3 by an immunoassay for squamous cell
carcinoma antigen (SCC), which detects both serpin B3 (SCCA1)
and serpin B4 (SCCA2), did not unravel any significantly different
concentrations between controls (0.4560.27 ng/L, n= 15), ACS
(0.6060.54 ng/L, n= 13) and stable CAD patients
(0.5760.29 ng/L, n = 15).
Plxdc2 was detected in endarterectomised plaque tissue as well,
although the immunohistochemical staining was weaker than that
of serpin B3 (Figures S2a). In coronary thrombi, Plxdc2 was
identified in cellular but not in extracellular parts (Figure S2b).
Immunoblotting using a commercial mAb against Plxdc2 did not
detect this antigen in plasma samples from patients and healthy
controls (Figure S2c).
JUP in Atherosclerotic Plaques and their Secretomes
Immunohistochemical analysis of endarterectomy specimens of
carotid arteries with the commercially available anti-JUP antibod-
ies mAb 2C9 showed strong immunoreactivity with dispersed cells
in the intima (Figure 3a). By their morphological appearance and
additional immunoreactivity with specific anti-CD68 antibodies,
these JUP-positive cells correspond to macrophages (Figures 3b).
The monoclonal mAb 2C9 (and its replacement 2G9)
antibodies did not identify JUP in plaque secretomes with its
expected size of 81 kD (JUP-81) (Figure 3c), but reacted strongly
with two proteins with apparent molecular masses of 30 kD
(JUP-30) and 55 kD (JUP-55), which may represent degradation
products, alternative splice variants, or homologues of JUP.
Both proteins were detected in atherosclerotic secretomes but
not in control secretomes. Similar results were obtained with
other antibodies against JUP (data not shown). The two bands
of 30 kD and 55 kD were also detected in the same secretomes
by scFv 25G5 (Figure 3d), the scFv by which JUP was initially
identified. ScFv 25G5 additionally reacted with a protein of
approximately 63 kD (JUP-63), which was not detected by the
commercial antibodies 2C9. We hypothesize that the 63 kD
protein represents a protein which is encoded by cDNA
FLJ60424 (Swissprot ID B4DE59), because it is highly similar
to JUP, has a predicted molecular weight of 63 kD and because
it was also identified by MS as one of the antigens
immunoprecipitated with scFv 25G5. In addition, binding of
the antibodies 2C9/2G9 and 25G5 to JUP-81, JUP-63 and
JUP-55 on Western blots could be reduced by competition with
soluble recombinant JUP (Figures 3e and 3f), further strength-
ening the hypothesis that these bands are indeed JUP isoforms.
The 745 and 563 amino acids encompassing sequences of JUP
and cDNA FLJ60424, respectively, share an identical N-
terminal sequence of 303 amino acids. MS identified four
peptides that can be assigned to both intact JUP and cDNA
FLJ60424. In addition, two and four peptides were identified
that were assigned to JUP and cDNA FLJ60424, respectively
(Figure S3).
Increased Plasma Levels of JUP Isoforms in Patients with
Coronary Artery Disease and Peripheral Arterial Occlusion
Disease
As depicted in Figure 4a, immunoblotting with the commercial
anti-JUP mAb 2C9 detected the 81 kD band of intact JUP in
plasma samples, which were depleted of albumin and IgG. The
only available commercial ELISA for JUP was found to be not
sensitive enough for detection of JUP in plasma samples. A semi-
quantitative immunoblotting approach revealed that median JUP
plasma levels are 2.4- and even 14.1-fold elevated in the plasma of
15 patients with stable CAD patients (p,0.01) and 11 patients
with ACS (p,0.01), respectively, as compared to 13 CAD-free
controls (Figure 4b). The three patients with very high JUP levels
(27-, 34-, and 64-fold higher than the median level in control
plasmas) did not differ from the other ACS patients by their
clinical presentation or troponin T levels (0.34, 0.54 and 4.5 mg/l,
respectively, compared to the range of 0.01 to 8.0 mg/l). After
removal of these three patients from the statistical analysis, JUP-81
was present in ACS plasmas at 10.6-fold higher median
concentration than in control plasma (p,0.01).
Plasma levels of JUP-81 correlated with plasma concentrations
of troponin T (r = 0.44, p,0.01), NT-proBNP (r = 0.41, p,0.01)
and CRP (r = 0.51, p,0.01). Correlations with plasma levels of the
soluble endothelial activation marker sVCAM-1 just missed the
level of significance (r = 0.31, p = 0.094). JUP concentrations did
not correlate with E-selectin plasma levels.
The presence of JUP isoforms in plasma from patients with
PAOD was analysed in four patients (Figure 5a). Besides JUP-81,
also JUP-55 and JUP-30 were detectable in these plasma samples.
To rule out the myocardial origin of JUP, we analysed plasma
samples of swine, in which myocardial infarction was artificially
introduced by ligation. Since swine JUP is highly homologous to
human JUP (98.5% homology on the amino acid level), mAb 2G9
is highly likely to react with swine JUP as well and 2G9 was
therefore applied to western blots containing samples of this model
of atherosclerosis-free myocardial damage. We did not find
detectable plasma levels of JUP-81, and JUP-30 was detected at
similar levels before and after ligation (Figure 5b).
JUP in Coronary Thrombi of ACS Patients
Thrombi isolated from coronary culprit lesions of two ACS
patients were analyzed by immunohistochemistry, using the
commercial mAb 2C9 for detection of JUP. As demonstrated in
Figure 6a, JUP was clearly detected in cells, as well as
extracellularly. By co-staining of JUP with an anti-CD68 mAb
as a macrophage marker, it was shown that cells expressing CD68
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clearly demonstrated JUP immunoreactivity as well (Figure 6b).
To unravel the isoform-identity of these anti-JUP-immunoreactive
proteins, two thrombi were dissolved in SDS-PAGE loading
buffer, separated by SDS-PAGE and immunoblotted with anti-
JUP mAb 2C9 (Figure 6c) and 25G5 (not shown). Neither the
81 kD nor the 63 kD protein bands could be detected. However,
the two protein bands of 55 and 30 kD, which were also found in
the secretomes, as well as several protein bands with estimated
molecular masses of 40, 45, and 100 kD were clearly detected in
the thrombus lysates.
JUP Isoforms are Expressed by Macrophages in vitro
Peripheral blood monocytes were isolated from buffy coats of
human blood donors and differentiated into macrophages by cell
cultivation for 2, 5, 7 and 9 days. Expression of JUP isoforms was
analysed by Western blotting. As shown in Figure 6d, the
Figure 3. Detection of JUP in plaques by immunohistochemistry and in secretome by immunoblotting. a) Overview of JUP
immunoreactivity on endarterectomised tissue. Strong staining in the atherosclerotic plaque tissue is observed. b) Clockwise from top left (400-fold
magnification): H&E staining (1), anti-CD68 (2), negative control (3), and anti-JUP staining (4). c and d) Six plaque secretomes (lanes 1–6), two control
secretomes (lanes 7 and 8) and GST-tagged JUP (lane 9, 107 kD) were immunoblotted with anti-JUP mAb 2C9 (c) and scFv 25G5 (d). e) Competition
experiment with mAb 2G9 (which replaced 2C9). Western blots containing recombinant GST-tagged JUP (lane 1, 107 kD), ACS plasma (lane 2), and
secretome (4.5 ml in lane 3 and 1.9 ml in lane 4) were incubated with mAb 2G9, which was (blot on the right) or was not (blot on the left) pre-
incubated with soluble, recombinant GST-tagged JUP protein. f) Competition experiment with scFv 25G5. Western blots containing different amount
of atherosclerotic plaque secretome (lane 1:4.5 ml, lane 2:1.9 ml, lane 3:0.9 ml, lane 4:0.4 ml) were incubated with scFv 25G5, which was (blot on the
right) or was not (blot on the left) pre-incubated with soluble, recombinant GST-tagged JUP protein. For all immunoblots: known molecular weights
of protein markers are depicted on the left and estimated molecular weights of detected protein bands are depicted on the right of both Western
blots.
doi:10.1371/journal.pone.0047985.g003
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expression of both JUP-55 and JUP-30 isoforms increased time-
dependently from day 2 to day 9.
Similar results were seen in THP1 monocytes that were
transformed into macrophages by treatment with phorbol esters
(Figure 7). All four JUP isoforms, namely JUP-81, JUP-63, JUP-55
and JUP-30, were detectable in the macrophage state, but except
JUP-30, none of them in the monocyte state (Figure 7a). Especially
the expression of JUP-81 and JUP-55 increased with time of
differentiation and cultivation.
Immunomapping of JUP Isoforms
Because of the clear signals, we used THP1-macrophages to
localize the three atypical JUP isoforms relative to JUP-81 by
the use of different anti-JUP antibodies with characterized
epitopes (Table 3). As demonstrated in Figure 7a, antibody LS-
C77817 (with its epitope located in the C-terminal region)
reacted with all four isoforms, although more weakly with JUP-
63 and JUP-30. Both JUP-63 and JUP-55 immunoreacted with
several antibodies with epitopes in the N-terminal proportion of
the molecule, including antibody ab134558 with an epitope
within amino acid residues 1–50 (Figure 7b). Therefore, JUP-63
and JUP-55 appear to represent N-terminal parts of JUP-81.
Antibody CP2971, with its epitope residing between amino acid
residues 545 and 555 only reacted with JUP-55 but not JUP-63
or JUP-30 (Figure 7c). This is in agreement with the alignment
of the first 303 amino acid residues of JUP-81 with JUP-63
(Figure S3). Also other antibodies with epitopes located at the
C-terminus of JUP-81 did not react with JUP-63. Because of
lacking reactivity of ab134558 (a.a 1–50) JUP-30 appears not to
share the first 50 amino acids with the other JUP isoforms and
may be located between amino acid residues 50 and 545.
Antibody CM1111 (Figure 7d), which has a C-terminal epitope,
Figure 4. JUP plasma levels in patients with ACS, CAD and controls. a) Detection of JUP-81 by immunoblotting with mAb 2C9. b) Semi-
quantitative analysis of Western blots. JUP plasma levels were correlated to JUP in a reference plasma that was run on each blot.
doi:10.1371/journal.pone.0047985.g004
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does only react with JUP-81, again indicating that JUP-55 and
JUP-30 are located in the N-terminal, rather than in the C-
terminal, part of JUP-81. Figure 8 provides a schematic
overview of the hypothetical positions of the different JUP
isoforms.
Discussion
By integrating subtractive phage display with MS we identified
JUP and its smaller isoforms as potential biomarkers of athero-
sclerosis. In fact, we provide three lines of evidence for this
conclusion. First, by using a hypothesis-free proteomics approach
we identified JUP-81 and JUP-63, a protein encoded by the
related cDNA FLJ60424, in secretomes of atherosclerotic plaques.
The fact that these proteins are released from the endarterecto-
mised tissue into the culture medium indicates that they might well
be released in vivo into the blood stream as well, which is a
prerequisite for any potential blood biomarker of atherosclerotic
processes. In line with this initial discovery, atherosclerotic but not
control secretomes contain proteins with apparent molecular
weights of 30, 55, 63 and 81 kD that immunoreact with our
discovering phage display antibody scFv 25G5, as well as
independent commercial antibodies against JUP. Immunoreactiv-
ity of several antibodies including the scFv screening antibody with
the JUP isoforms could be reduced by pre-incubation of the
antibodies with JUP, indicating that these bands do represent JUP
isoforms. Second, compared to healthy controls, median concen-
trations of JUP-81 were increased by factors higher than 2 and 14
in plasma of patients with stable CAD and ACS, respectively.
Third, macrophages of endarterectomized plaques as well as
Figure 5. Detection of JUP isoforms in plasma from PAOD patients with atherosclerosis and in plasma from a swine model of
myocardial infarction without atherosclerosis and plaque rupture. a) Western blot containing recombinant GST-tagged JUP (lane 1, 107 kD),
ACS plasma (lane 2), control plasma (lane 3) and plasma from four PAOD patients (lanes 4 to 7) were detected with mAb 2G9 (which replaced 2C9).
JUP-55 and JUP-30 are clearly detected besides JUP-81. b) Western blot containing recombinant GST-tagged JUP (lane 1, 107 kD), ACS plasma (lane
2), control plasma (lane 3) and plasma samples from swine before ligation (lanes 4 and 7), three hours after ligation (lanes 5 and 8) and three days
after ligation (lanes 6 and 9) were detected with mAb 2G9. JUP-81 was not detected in the swine samples, whereas JUP-30 and a protein band with a
slightly larger molecular weight were detected with similar intensities before and after ligation.
doi:10.1371/journal.pone.0047985.g005
Junction Plakoglobin, Biomarker of Atherosclerosis
PLOS ONE | www.plosone.org 9 October 2012 | Volume 7 | Issue 10 | e47985
monocytes, macrophages and fibrin platelet clots of coronary
thrombi of ACS patients show a strong anti-JUP-immunoreactiv-
ity. Lysates of thrombi contained the same 55 kD JUP-antigen
which was detected in atherosclerotic secretomes as well as
cultivated monocyte-derived macrophages.
JUP is a protein component of desmosomes, which are junction
complexes with essential structural functions in tissues that
experience mechanical stress [25]. Desmosomes connect neigh-
bouring cells through their transmembrane cadherins (desmocollin
and desmoglein). The cytoplasmic tails of cadherins are connected
through JUP, plakophilin and desmoplakin to the intermediate
filaments. The essential physiological role of JUP for regular
function of desmosomes in the myocardium is indicated by the
findings of premature cardiac death of JUP knockout mice [26,27]
and arrhytmogenic right ventricular cardiomyopathy in patients
carrying mutations in the JUP gene [28,29]. Furthermore, the
importance of JUP for endothelial integrity is indicated by the
results of several in vitro experiments [30,31]. Recent data by Sun
et al. demonstrated that overexpression of the disintegrin and
metalloproteinase 15 (ADAM15), a metalloprotease that was
recently identified as a regulator of endothelial permeability, led to
dissociation of gamma-catenins (JUP) from VE-cadherin [32]. At
least in theory, the increased JUP plasma levels in ACS and CAD
patients may hence be explained by either myocardial or
endothelial damage or both. In agreement herewith, concentra-
tions of JUP-81 in human plasma correlated with other
biomarkers of myocardial damage (troponin T, r = 0.44) and
dysfunction (NT-proBNP, r = 0.41) as well as endothelial dysfunc-
tion (sVCAM1, r = 0.31). In addition, we found that macrophages
of endarterectomized plaques and coronary thrombi, as well as
macrophages differentiated either from peripheral blood mono-
cytes or THP1 monocytes in vitro, express JUP isoforms. This
finding was unexpected, since macrophages are single cells that do
not form continuous and adherent stretches of cells, which are
interconnected by desmosomes or junctions. In addition, JUP
isoforms could be detected in plasma from patients with PAOD
(having peripheral atherosclerotic plaques without suffering a
myocardial infarction), but not in a swine model in which non-
atherosclerotic myocardial infarction was induced by ligation.
Taken together, these findings indicate that JUP isoforms are
produced by macrophages in the atherosclerotic plaques, thrombi
and differentiated from monocytes in vitro, rather than being
released from the myocardium.
In addition to JUP-81, a 63 kD JUP-homologue encoded by
cDNA FLJ60424, was identified by both MS and Western
blotting of atherosclerotic secretomes. Both the 81 kD- and
Figure 6. Detection of JUP in thrombi. a) Tissue section of a coronary thrombus stained with anti-JUP mAb 2C9 and labelled goat anti-mouse
antibodies (brown) (1, on the left) or with the secondary labelled goat anti-mouse antibody only as a negative control (2, on the right). Nuclei are
stained in blue. Immunoreactivity of JUP is detected intra- as well as extracellularly. b) Tissue section of a coronary thrombus, double-stained with
anti-JUP mAb 2C9 (red) and the macrophage marker anti-CD68 mAb (black). In addition, an extracellular staining of the fibrin platelet clot was
observed. c) Detection of JUP in lysates of coronary thrombi by immunoblotting. A Western blot with recombinant GST-tagged JUP (lane 1, 107 kD),
plaque secretome (lane 2), plasma from an ACS patient (lane 3), and lysates of two thrombi (lanes 4 and 5) were immunoblotted with mAb 2C9. d and
e) Western blot of macrophages, that differentiated from monocytes isolated from peripheral blood on day 2 (lane 1), day 5 (lane 2), day 7 (lane 3)
and day 9 (lane 3), was immunoblotted with mAb 2G9 (which replaced 2C9) (d) and an anti-GAPDH mAb (e) as a loading control.
doi:10.1371/journal.pone.0047985.g006
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Figure 7. Detection of JUP isoforms in macrophage-like cells. To differentiate THP1 into macrophage-like cells, cells were stimulated by PMA
for 1, 2, 3 and 4 days. JUP isoforms were analyzed by Western blotting using anti-JUP antibodies LS-C77817 (a), ab134558 (b), CP2971 (c) and CM1111
antibody (d). 200, 100, 50 and 25 ng of recombinant GST-tagged JUP was used as positive control (lanes 1–4, respectively). Lane 5 contains lysates of
undifferentiated THP1 cells (monocytes) and lanes 6–9 contain lysates of differentiated THP1 cells (macrophages) after 1, 2, 3 and 4 days of
differentiation (note opposite order of loading in panel b)). b-actin was employed as a loading control. CP2971 reacts only weakly with recombinant
JUP on Western blots (no visible reaction detected here).
doi:10.1371/journal.pone.0047985.g007
Table 3. Reactivities of ten different commercial anti-JUP antibodies with the four JUP isoforms.
Antibody Immunogen (epitope) Rec. JUP JUP-81 JUP-63 JUP-55 JUP-30
ab134558 a.a. 1–50 + + + + -
LS-C21269 full-length JUP (a.a. 45–114) + + - - -
CP2971 a.a. 545–555 + - - + -
610253 a.a. 553–738 + + - - -
LS-C118399 C-terminal region + + - - -
LS-C77817 C-terminal region + + +/2 + +
LS-B1216 C-terminal region + - - + -
CM1111 C-terminal region + + - - -
LS-B4364 (2G9) full-length JUP + + - + +
P8087 chicken JUP + + + + -
a.a. = amino acids; Rec. JUP= recombinant, GST-tagged JUP.
doi:10.1371/journal.pone.0047985.t003
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63 kD-proteins were immunoprecipitated from secretomes with
scFv 25G5 and were recognized by several commercial
antibodies with epitopes in the N-terminus of JUP-81. Further-
more, reactivity of scFv 25G5 with JUP-63 could be competed
by pre-incubation of the antibody with recombinant JUP-81.
This suggests that scFv 25G5 recognizes an epitope that is
shared by JUP-81 and JUP-63 and is thus likely to be located in
the common N-terminal part of both proteins. Currently,
nothing is known about the 63 kD JUP isoform, since it has
only been described as a coding DNA submitted into the
databases of EMBL [33], GenBank [34] and DDBJ [35].
Cloning and expression of JUP-81 and JUP-63 in bacterial or
mammalian cells are needed to gain more insight into the
location of the epitope that is recognized by 25G5 and to
generate antibodies and standards for sandwich ELISAs to
quantify these proteins in patient samples. In addition, high-
affinity antibodies that specifically recognize JUP-63 will be
essential to characterize its tissue expression pattern and
function.
It is not clear whether JUP-55 and JUP-30 are degradation
products of JUP-81 and/or JUP-63, or if these two proteins
represent additional, as yet unknown (alternative splicing) variants
of JUP. Blast database searches with the JUP sequence identified
highly identical, smaller sequences that could represent the 30 kD
band, but no sequence was found that could correspond to a
protein band of 55 kD. Mapping with commercial antibodies
revealed that JUP-55 is located in the N-terminal part of JUP and
that JUP-30 may be located somewhere between amino acid
residues 50 and 545 (Figure 8). In further studies, JUP isoforms
(fragments) will be identified by mass spectrometry to gain
information about their sequences and origin.
In conclusion, this is the first report of JUP and its isoforms in
the context of atherosclerosis and cardiovascular disease. The
increased JUP concentrations in plasma of patients with stable
CAD and ACS suggest JUP and its isoforms as potential
biomarkers for atherosclerosis. The development of quantitative,
high-throughput immunoassays for JUP and for the JUP isoforms,
as well as their subsequent application in different clinical studies
are needed to validate JUP as a biomarker for diagnosis, prognosis
or monitoring of atherosclerosis.
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Figure 8. Schematic overview of the four different JUP isoforms. JUP-81 and JUP-63 have an identical N-terminus (the N-terminal 303 amino
acids), and JUP-63 further shares its C-terminus with cytokeratin 19 (K1C19). The sequences of JUP-55 and JUP-30 are currently unknown but they
contain epitopes that are shared with JUP-81 and are thought to be located in the N-terminal region of native JUP. JUP-30 lacks (at least) the N-
terminal 50 amino acids of JUP-81. JUP-81, which is also referred to as gamma-catenin, is furthermore homologous to beta-catenin. Amino acids 1,
303 and 745 of JUP-81 are indicated with arrows.
doi:10.1371/journal.pone.0047985.g008
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